YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.
To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.
A replay of the webcast will be available for 30 days following the conclusion of the event.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
- Precore Gold Granted Option to Acquire Arikepay Porphyry Gold-Copper Property in Peru - April 23, 2025
- Mullen Group Ltd. Reports 2025 First Quarter Financial Results - April 23, 2025
- Port of Helsingborg Advances Digital Transformation with N4 Terminal Operating System, Reduces Rehandles by 50 Percent - April 23, 2025
